Drug Database
ME

meningococcus B & C vaccine

✓ Approved

Abivax · 疫苗 · 疫苗

什么是 meningococcus B & C vaccine?

meningococcus B & C vaccine 是一种疫苗,由Abivax研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司Abivax
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

meningococcus B & C vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →
PubMedBMC genomics2026-11-18

Genomic characterization and immunoinformatics analysis of the Brucella melitensis vaccine strain BA0711.

Zhang Mengqi M, Cheng Yiwen Y, Yin Zhenghang Z, Niu Shihua S et al.

B. melitensis BA0711 is a novel genetically engineered attenuated live vaccine strain constructed by the targeted deletion of the cold shock protein A (CspA) gene. While previous studies demonstrated its safety and protective efficacy in animals, its underlying comparative genomic characteristics, pathogenicity evolution, and theoretically predicted immunogenic potential from a genome-wide perspective remain to be systematically elucidated. In this study, a high-quality complete genome of B. melitensis BA0711 was obtained using a hybrid next-generation sequencing and third-generation sequencing strategy. The genome comprised two closed circular chromosomes totaling 3,310,449 bp, with no plasmids or exogenously acquired antimicrobial resistance genes detected. Phylogenetic, multilocus sequence typing, and whole-genome similarity analyses determined B. melitensis BA0711 as the ST8 lineage and revealed its closest genetic relationship with B. melitensis M28 among the reference strains analyzed. Whole-genome collinearity and pangenome analyses further revealed a highly conserved genomic backbone and macro-syntenic organization. Horizontal gene transfer analysis identified 263 putative horizontally transferred genes, including a pathogenicity-associated genomic island, GI_6, containing multiple core lipopolysaccharide biosynthesis and modification genes. Comparative profiling of core virulence factors confirmed the targeted absence of cspA and revealed lineage-associated amino-acid variation in several virulence-related proteins. Following host-homology screening, immunoinformatics analysis of 78 core virulence-associated proteins retained 5,212 non-host-homologous MHC-I strong-binding epitope records, 7,476 non-host-homologous MHC-II strong-binding epitope records, and 574 non-host-homologous linear B-cell epitope candidates. Cgs and BPE043 were prioritized as representative T-cell epitope-rich proteins. Sequential screening based on antigenicity, allergenicity, toxicity, and HLA-binding breadth further identified four representative peptides: SSAAISSAF, LSMFVAPTF, SLNSLSVDIARAIDH, and RRFIRQLPLYKVPLE. AlphaFold 3 modeling and complementary HPEPDOCK analysis supported structurally plausible presentation of these peptides within the corresponding canonical HLA-binding grooves. The targeted deletion of cspA was additionally confirmed by PCR. Our whole-genome comparative analysis elucidates the genomic architecture and evolutionary background of B. melitensis BA0711. The strain possesses a conserved ST8-associated genomic background and shows the closest genetic relationship with B. melitensis M28 among the analyzed reference strains. Systematic profiling of genome organization, putative horizontally transferred genes, and virulence-factor variation provides a molecular framework for understanding this vaccine strain. Moreover, immunoinformatics analysis prioritized Cgs and BPE043 as representative T-cell epitope-rich proteins and identified four peptide candidates with computationally plausible HLA-presentation modes. These in silico findings identify experimentally testable candidates for further investigation but require experimental validation of HLA binding and immunogenicity.

PMID 43046134
阅读全文 →
PubMedBMC pregnancy and childbirth2026-11-18

Analysis of 58 cases of cervical pregnancy and literature review.

Li Zhuyin Z, Jia Ruolin R, Huang Jie J, Shen Qi Q et al.

This study aimed to investigate the efficacy and prognosis of different treatment modalities in patients with cervical pregnancy. Clinical data of 58 patients diagnosed with cervical pregnancy admitted to the Obstetrics and Gynecology ward of the Third Affiliated Hospital of Zhengzhou University during the period from September 2014 to September 2024 were retrospectively analyzed as the study subjects, and according to the different treatment modes of the patients, patients were categorized into Group A[n = 13, treated with methotrexate (MTX) + mifepristone drug therapy in addition to ultrasound-guided uterine curettage], Group B [n = 19, treated with UAE in addition to ultrasound-guided uterine curettage] and Group C [n = 26, treated with direct ultrasound-guided uterine curettage(D&C alone)]. The general clinical data and intraoperative and postoperative conditions of the patients in the three groups were collected by retrospective analysis and statistical analysis. A total of 58 patients with cervical pregnancy were included and divided into three groups: Group A (MTX + mifepristone + D&C, n = 13), Group B (UAE + D&C, n = 19), and Group C (D&C alone, n = 26). There were no significant differences among the three groups in baseline characteristics, including age, gestational age, mode of conception, gravidity, preoperative β-hCG levels, and gestational sac size(Width and Thickness) ( P > 0.05). No patient in any group required a hysterectomy. Intraoperative blood loss showed no significant difference among groups (P > 0.05), although severe bleeding (≥ 300 mL) occurred more frequently in Group C (n = 8) than in Group A (n = 2) and Group B (n = 3). Group A had significantly longer hospital stays compared with Group B and Group C (P < 0.05). Hospitalization costs were significantly lower in Group C than in Groups A and B (P < 0.05). There was no significant difference in postoperative day 3 β-hCG levels among the three groups (P > 0.05). However, the time to β-hCG normalization was significantly shorter in Groups A and B than in Group C (P < 0.05). In the case of cervical pregnancy, individualized and combined treatment regimens should be chosen according to the patient's condition to achieve optimal therapeutic outcomes.

PMID 43046155
阅读全文 →
PubMedChemical communications (Cambridge, England)2026-11-18

Si-O boron-based anion engineering stabilizes the electrolyte interphase for reversible magnesium anodes.

Zhou Xinyi X, Nie Jingna J, Zhang Lu L, Cui Zhihong Z et al.

An efficient boron-based electrolyte with tris(trimethylsilyl) borate B(OTMS)3 (BTMS) and ethylmagnesium chloride (EtMgCl) was synthesised for magnesium batteries. The (EtMgCl)2-B(OTMS)3 electrolyte consists of a [MgCl·3THF]+ cation and a unique anion, B(OSiMe3)3(CH2CH3)-. The anion-derived B-O/Si-O/Si-C interphase engineering paves a new avenue for the rational design of magnesium electrolytes.

PMID 43049366
阅读全文 →
PubMedZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery2026-11-18

[Effect of sequential multi-dose tranexamic acid administration on perioperative blood loss in cervical posterior single-door laminoplasty and its safety].

Cui Wei W, Li Xiuzhi X, Li Yuwei Y, Gu Shifeng S et al.

To investigate the effect of sequential multi-dose intravenous administration of tranexamic acid (TXA) on perioperative blood loss and inflammatory response in patients undergoing cervical posterior single-door laminoplasty (LMP), and to evaluate its safety. A prospective study was conducted in patients diagnosed with multi-level cervical spondylotic myelopathy, who underwent cervical posterior single-door LMP between January 2023 and June 2024. Using a computer-generated randomization table, patients were allocated into three groups. Placebo control group (group A): received 100 mL of normal saline intravenously at 30 minutes before incision (after anesthesia induction); the same dose was repeated every 5 hours for a total of 3 administrations. Single-dose control group (group B): received 1.0 g of TXA (dissolved in 100 mL normal saline) at 30 minutes before incision, followed by 100 mL of normal saline every 5 hours for a total of 2 additional doses. Sequential multi-dose group (group C): received 1.0 g of TXA (dissolved in 100 mL normal saline) at 30 minutes before incision, with an additional 1.0 g of TXA administered intravenously at 5 hours and 10 hours postoperatively, for a total dose of 3.0 g. A total of 120 patients met the selection criteria and were included in the study. After excluding lost-to-follow-up and withdrawn patients, 39 cases in group A, 37 in group B, and 38 in group C were included in the final analysis. There was no significant difference between groups (P>0.05) in age, gender, height, body weight, body mass index, comorbidities (hypertension, diabetes), and preoperative hematocrit (HCT), hemoglobin, D-dimer (D-D), interleukin 6 (IL-6), and C-reactive protein (CRP) levels. The primary outcome was total blood loss (TBL). Secondary outcomes included intraoperative blood loss (IBL), postoperative blood loss (PBL), drain removal time (DRT), HCT, D-D, IL-6, CRP, allogeneic blood transfusion rate, and incidence of complications. Blood loss assessment: TBL, PBL, DRT, postoperative decline in HCT, and the allogeneic blood transfusion rate were all the lowest in group C, followed by group B, and the highest in group A, with significant differences between groups (P<0.05). The IBL was significantly lower in groups B and C than in group A (P<0.05), while there was no significant difference between groups B and C (P>0.05). Changes in inflammatory indicators: the levels of D-D and IL-6 in 3 groups reached peak at 1 day, the level of CRP reached peak at 3 days, and both decreased at 5 days, but still remained higher than preoperative levels, with significant differences (P<0.05). At different time points, the levels of D-D, IL-6, and CRP were significant lower in group C than in groups A and B (P<0.05), and in group B than in group A (P<0.05). Safety evaluation: During the 30-day postoperative follow-up, no deep vein thrombosis, pulmonary embolism, incisional infection, incisional hematoma, or TXA-related allergic reaction occurred in 3 groups. Sequential multi-dose TXA administration effectively reduces perioperative blood loss in cervical posterior single-door LMP, suppresses postoperative hyperfibrinolysis and inflammatory response, shortens drainage duration, and does not increase the risk of thromboembolic events. This regimen represents a safe and effective optimization strategy for perioperative blood management in LMP.

PMID 43046568
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcus B & C vaccine